Biogen (BIIB)
(Delayed Data from NSDQ)
$194.12 USD
-1.69 (-0.86%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $193.51 -0.61 (-0.31%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
BIIB 194.12 -1.69(-0.86%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Lilly Gets FDA Approval for Eczema Drug Ebglyss
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
Other News for BIIB
IN BRIEF: Biogen's dapirolizumab shown effective against lupus
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
Eli Lilly's Alzheimer's therapy approved in Japan
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
Overweight quality stocks with positive EPS revisions - MS